Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego

BOSTON and STOCKHOLM, Dec. 2, 2018 /PRNewswire/ -- Aprea Therapeutics presented results at the 2018 ASH Annual Meeting from its Phase Ib/II clinical study in MDS. The ongoing study is evaluating the safety and efficacy of APR-246 in combination with azacitidine for the treatment of TP53...

from PR Newswire: https://ift.tt/2AIjLVd